NCT03772678View on ClinicalTrials.gov

A Phase I Study to Evaluate LSALT Peptide

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
None - Study is to Determine Safety in Healthy Participants
Interventions
DRUG

LSALT peptide

novel 16 amino acid peptide

OTHER

0.9% Saline

saline

Trial Locations (1)

3004

Nucleus Network Ltd., Melbourne

Sponsors
All Listed Sponsors
lead

Arch Biopartners Inc.

INDUSTRY